Itralent-SB 130 Capsule contains Itraconazole 130 mg, a broad-spectrum triazole antifungal agent used primarily for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itralent-SB 130 is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. It is particularly effective against infections caused by dermatophytes, yeasts, and molds. The capsule formulation allows for oral administration, with absorption enhanced when taken with food. Itraconazole is metabolized extensively in the liver via the cytochrome P450 system and has a relatively long half-life, permitting once or twice daily dosing depending on the severity and type of infection. Caution is advised in patients with liver impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to itraconazole’s inhibitory effect on CYP3A4 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Itralent-SB 130 Capsule should be used under medical supervision with appropriate monitoring.